Activity Type: Knowledge-based
CE Credit: No CE is offered with this activity.
Activity Fee: Members/Non-Members - Free
Activity Date: May 20, 2020
Learn about the clinical use of remdesivir for the treatment of patients with COVID-19 by the pharmacy team at Nebraska Medicine. Remdesivir has been added to the FDA Emergency Use Authorization list for the treatment of hospitalized patients with severe COVID-19 disease. The activity will cover treatment and clinical experience with remdesivir, supportive care for COVID-19 patients, and discussion of remdesivir clinical trial results. Nebraska Medicine and the University of Nebraska Medical Center have led the world in treatment, training, and quarantine methods for highly infectious diseases since caring for patients during the 2014 Ebola outbreak.
- Clinical Experience with Remdesivir
- Monitoring and Supportive Care
- What’s Next for the Adaptive COVID Treatment Trial?
Scott Bergman, PharmD, BCPS, BCIDP, FCCP, FIDSA
Pharmacy Coordinator, Antimicrobial Stewardship and PGY2 Residency Program Director, Infectious Diseases Pharmacy at Nebraska Medicine and Clinical Associate Professor, UNMC College of Pharmacy
Bryan Alexander, PharmD, BCPS, BCIDP, AAHIVP
Infectious Diseases/Antimicrobial Stewardship Pharmacist at Nebraska Medicine
Logan Olson, PharmD, BCCCP
Critical Care Pharmacy Specialist at Nebraska Medicine
The webinar will be moderated by Eric Maroyka, ASHP’s Senior Director, Center on Pharmacy Practice Advancement, and David Warner, ASHP’s Director, Center on Practice Development.